President Trump has struck a trade deal with the European Union, which includes a 15% tariff on most goods. However, it’s important to note that drugs are excluded from this deal, as an ongoing investigation in the U.S. continues.
EU officials are optimistic that when everything settles down, drug tariffs will likely remain below 15%. Still, there are concerns, as some prescription drugs made outside the U.S. could face tariffs as high as 200%.
Reportedly, Trump is keeping the pressure on drug tariffs, using it as a way to push for more U.S. production in the pharmaceutical sector. But it seems he often voices frustrations over high drug costs and the expenses associated with imposing steep tariffs on these products.
Back in 1994, during World Trade Organization negotiations, many major trading partners agreed to exempt most medications from customs duties through an initiative aimed at protecting public health. This was largely rooted in the belief that medications are too critical to be swept up in political tariff debates, yet it appears Trump is seeking to revisit this agreement.
One thing stands out: imposing tariffs on medicines won’t effectively address issues with China. According to analysis, only about 3% of active pharmaceutical ingredients for brand-name drugs are sourced from China, and a mere 2% from India. For generics, those numbers rise to 8% and 35%, respectively.
Europe is actually a strong player in this field, accounting for 43% of the active ingredients used in brand-name drugs, while the U.S. produces around 15%. Ireland, in particular, has become a center for pharmaceutical manufacturing, thanks in part to favorable corporate tax rates—something that Trump seems to recognize as a business advantage.
As for jobs, the U.S. Bureau of Labor Statistics reports that the “Medicine and Medical Manufacturing” field employed over 340,000 people in 2023, with an average salary around $87,170. That’s a solid footprint. Yes, while manufacturing jobs could eventually return to the U.S., the process will take time due to the complexity and high costs of setting up new facilities. Plus, many manufacturers are leaning more toward automation.
Moreover, there’s the global landscape to consider. Many countries, including EU nations, are keen to produce medications domestically, similar to how they prefer to see foreign cars made in local factories.
On the positive side, Trump’s cuts to regulations and his tax incentives could foster a better environment for U.S. manufacturing. However, these changes might be short-lived, vulnerable to reversal by future administrations.
It might be more effective for the U.S. to consider reinstating the manufacturing tax credits similar to those that once benefited Puerto Rico. The island had a thriving pharmaceutical sector until these incentives were phased out in 1996, which left it economically struggling.
In terms of national security, Europe stands as one of the U.S.’s strongest allies. There seems to be little to fear regarding the safety of drugs produced there.
High drug prices remain a significant concern. Yes, new medications, particularly biologics for rare diseases, can come with hefty price tags. Yet, imposing tariffs only serves to further inflate costs for drugs produced abroad.
For diseases like cancer, many innovative treatments emerge from small biotech firms that rely heavily on investors and might struggle to absorb tariff costs. The increased price burden gets passed on, which isn’t ideal for anyone.
Encouraging the redevelopment of the manufacturing sector might push some nations toward implementing mandatory licensing, allowing other firms to produce patented medications without prior consent from the patent holders. This might not be the most politically savvy route, especially if it drives companies away.
Overall, pharmaceutical tariffs are likely one of the least beneficial strategies possible. Trump’s approach has stirred other sectors to re-shore their operations through tax and regulatory reform. Dismantling the zero-to-zero initiative is arguably counterproductive.
